

Naveen Chandra Suryadevara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8412164/publications.pdf>

Version: 2024-02-01

30
papers

4,933
citations

516561

16
h-index

477173

29
g-index

41
all docs

41
docs citations

41
times ranked

9967
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. <i>IScience</i> , 2022, 25, 103602.	1.9	6
2	Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. <i>Nature Biotechnology</i> , 2022, 40, 1270-1275.	9.4	27
3	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
4	Structural mapping of antibody landscapes to human betacoronavirus spike proteins. <i>Science Advances</i> , 2022, 8, eabn2911.	4.7	28
5	Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape. <i>STAR Protocols</i> , 2022, 3, 101387.	0.5	8
6	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
7	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. <i>Cell Host and Microbe</i> , 2021, 29, 44-57.e9.	5.1	937
8	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
9	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. <i>Cell</i> , 2021, 184, 2316-2331.e15.	13.5	321
10	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021, 2, 100313.	3.3	56
11	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	2.9	67
12	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
13	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. <i>Cell Reports</i> , 2021, 37, 109784.	2.9	20
14	Pan-ebolavirus protective therapy by two multifunctional human antibodies. <i>Cell</i> , 2021, 184, 5593-5607.e18.	13.5	21
15	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. <i>Nature Immunology</i> , 2020, 21, 1506-1516.	7.0	563
16	Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines. <i>ACS Nano</i> , 2020, 14, 9904-9916.	7.3	97
17	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	13.7	956
18	Heterotypic immunity against vaccinia virus in an HLA-B*07:02 transgenic mousepox infection model. <i>Scientific Reports</i> , 2020, 10, 13167.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Defective Antigen Presentation Leads to Upregulation of PD1 and IL-10 in HIV-TB Co-Infection. Journal of Interferon and Cytokine Research, 2020, 40, 310-319.	0.5	0
20	Genotyping of Mycobacterium leprae for understanding the distribution and transmission of leprosy in endemic provinces of China. International Journal of Infectious Diseases, 2020, 98, 6-13.	1.5	9
21	Nur77 controls tolerance induction, terminal differentiation, and effector functions in semi-invariant natural killer T cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17156-17165.	3.3	17
22	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nature Medicine, 2020, 26, 1422-1427.	15.2	450
23	Molecular surveillance of antimicrobial resistance and transmission pattern of Mycobacterium leprae in Chinese leprosy patients. Emerging Microbes and Infections, 2019, 8, 1479-1489.	3.0	16
24	Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8 ⁺ Lung-Resident Memory T Cells. ACS Nano, 2019, 13, 10939-10960.	7.3	89
25	Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective. Frontiers in Immunology, 2017, 8, 1858.	2.2	56
26	Association of Taq I, Fok I and Apa I polymorphisms in Vitamin D Receptor (VDR) gene with leprosy. Human Immunology, 2015, 76, 402-405.	1.2	24
27	Influence of Intron II microsatellite polymorphism in human toll-like receptor 2 gene in leprosy. Human Immunology, 2013, 74, 1034-1040.	1.2	18
28	Genetic association of G896A polymorphism of TLR4 gene in leprosy through family-based and case-control study designs. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, 107, 777-782.	0.7	6
29	LRRK2 and RIPK2 Variants in the NOD 2-Mediated Signaling Pathway Are Associated with Susceptibility to Mycobacterium leprae in Indian Populations. PLoS ONE, 2013, 8, e73103.	1.1	45
30	IL-10 high producing genotype predisposes HIV infected individuals to TB infection. Human Immunology, 2012, 73, 605-611.	1.2	29